Earlier clinical response predicts low rates of radiographic progression in biologic-naive patients with active psoriatic arthritis receiving guselkumab treatment.

ABSTRACT:

Objective

Assess relationship between earlier clinical improvement and radiographic progression (RP) over 2 years in guselkumab-treated patients with active psoriatic arthritis (PsA).

Method

Post hoc analyses combined data from DISCOVER-2 biologic-naïve adults with active PsA randomized to either guselkumab 100 mg every 4 weeks (Q4W) or guselkumab at W0, W4, then Q8W. Correlations (Spearman's coefficient) between baseline disease parameters and total PsA-modified van der Heijde-Sharp (vdH-S) score were examined. Repeated-measures mixed models, adjusted for known RP risk factors, assessed the relationship between Disease Activity Index in PsA (DAPSA) improvement, DAPSA improvement exceeding the median or the minimal clinically important difference (MCID), or DAPSA low disease

SUBMITTER: Mease PJ 

PROVIDER: S-EPMC10774160 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature